To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

And other biotech news brought to you by The Readout.

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

A newly approved Alzheimer’s drug is set to be administered for the first time in Taiwan on Monday, Far Eastern Memorial Hospital in New Taipei City announced yesterday. Kisunla, the brand name of the ...

Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

They do not treat the cause of Alzheimer’s disease. Kisunla offers a new approach to treat early Alzheimer’s disease. It targets the root cause of Alzheimer’s to help slow how quickly ...

Kisunla (donanemab-azbt) is a prescription drug that’s used to treat Alzheimer’s disease in adults. This drug currently isn’t known to interact with other drugs. Note: As a person’s ...

The decision to register the therapy was supported by data from the Phase III TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 trials.

Kisunla is the first amyloid-targeting therapy for people with Alzheimer's registered in Australia and the only amyloid plaque-targeting therapy with evidence to support stopping therapy when ...